Deals Shaping The Medical Industry, July 2015
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2015.
You may also be interested in...
Arcturus's Differentiated RNA Technology Faces First Clinical Test In 2017
Emerging Company Profile: San Diego-based Arcturus Therapeutics has developed technology for the targeted delivery of RNA therapeutics, which Johnson & Johnson's Janssen subsidiary will evaluate for the first time in humans in a clinical trial starting as early as this year for the partners' hepatitis B drug candidate.
Off-Label Use Final Rule: US FDA Declines To Focus Solely On Promotional Claims
In final rule describing the types of evidence the agency will consider in determining the ‘intended use’ of a product, FDA rejects industry requests to exclude ‘circumstances surrounding distribution’ and product design or composition.
US FDA Publishes, Then Withdraws, PDUFA Rates Because Process ‘May Not Be Well Understood’
User fees for FY 2021 were set to increase nearly 11%, but could have gone even higher; a new notice will be issued but timing is unclear.